Meniere's Disease Clinical Trial - Repurposed use of allergic rhinitis and allergic asthma drug to reduce vertigo and hearing loss in Meniere's Disease
The House Institute Foundation (HIF) is currently looking for subjects 18 years of age or older who have been diagnosed with Meniere’s disease to enroll in a clinical research trial. Participants must have been diagnosed with Meniere’s Disease in only one ear, although they may have hearing loss from another cause in the opposite ear. They must also have known or suspected environmental allergies, and not currently be taking allergy shots. There are some other exclusion and inclusion criteria which our Clinical Coordinator, Ms. Mahta Marefat, can review with you.
The purpose of the trial is to see whether the use of a medication already approved and widely used in patients with allergy or asthma has any effect on the symptoms of Meniere’s disease. It is a double-blinded, placebo-controlled trial. This means that half of the patients will be given the medication and half will be given a placebo. Neither the patient nor the doctor will know which medication has been given. The medication or placebo will be provided at no charge. Patients will be asked to take the medication for three months and will be required to have office visits and hearing testing at the clinic located in Los Angeles, CA at the trial onset, monthly for three months, and a final exam at 6 months. There is no charge for participating in the trial, and a small compensation will be given. Travel assistance is also provided.
If you are interested in participating in the trial, please contact Ms. Mahta Marefat at [email protected] or by phone at (213) 770-1808. She will then communicate more with you about the study. We appreciate your support of our research on Meniere’s disease at the House Institute Foundation.
Mahta - You can post clinical trials recruiting participants on VeDA's website here: https://vestibular.org/clinical-trial-recruitment/,
You can also contact us at [email protected] for more support.